ArticleJCI insight2017
Essential role for CCR6 in certain inflammatory diseases demonstrated using specific antagonist and knockin mice.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.International journal of molecular sciences · 2017Pooled it
- Article
- CCL20-CCR6 axis in autoimmune disease and cancer progression: clinical and therapeutic implications.Cell communication and signaling : CCS · 2026Review
- Identification of hub genes for psoriasis and thyroid cancer using bioinformatics analysis.Discover oncology · 2025Article
- Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective.Frontiers in immunology · 2025Review
- Fc-enhanced anti-CCR6 antibody elicits robust therapeutic effects across multiple autoimmune diseases.Frontiers in immunology · 2025Article
- Targeting IL-1 controls refractory pityriasis rubra pilaris.Science advances · 2024Article
- The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis.Journal of psoriasis and psoriatic arthritis · 2023Review
- Chemoselective Methionine Labelling of Recombinant Trastuzumab Shows High In Vitro and In Vivo Tumour Targeting.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity.PloS one · 2023Article
- Article
- Review
- Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.Cancer cell · 2021Article
- Effects of B cell-activating factor on tumor immunity.JCI insight · 2020Article
- Interleukin-17A and Keratinocytes in Psoriasis.International journal of molecular sciences · 2020Review
- The EGFR-ERK/JNK-CCL20 Pathway in Scratched Keratinocytes May Underpin Koebnerization in Psoriasis Patients.International journal of molecular sciences · 2020Article
- The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases.Frontiers in immunology · 2020Review
- Is CCR6 Required for the Development of Psoriasiform Dermatitis in Mice?The Journal of investigative dermatology · 2019Article
- CNS infection and immune privilege.Nature reviews. Neuroscience · 2018Review
- Pleiotropic Immune Functions of Chemokine Receptor 6 in Health and Disease.Medicines (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemokine receptor CCR6 marks subsets of T cells and innate lymphoid cells that produce IL-17 and IL-22, and as such may play a role in the recruitment of these cells to certain inflammatory sites. However, the precise role of CCR6 has been controversial, in part because no effective monoclonal antibody (mAb) inhibitors against this receptor exist for use in mouse models of inflammation. We circumvented this problem using transgenic mice expressing human CCR6 (hCCR6) under control of its native promoter (hCCR6-Tg/mCCR6-/-). We also developed a fully humanized mAb against hCCR6 with antagonistic activity. The expression pattern of hCCR6 in hCCR6-Tg/mCCR6-/- mice was consistent with the pattern observed in humans. In mouse models of experimental autoimmune encephalomyelitis (EAE) and psoriasis, treatment with anti-hCCR6 mAb was remarkably effective in both preventive and therapeutic regimens. For instance, in the imiquimod model of psoriasis, anti-CCR6 completely abolished all signs of inflammation. Moreover, anti-hCCR6 attenuated clinical symptoms of myelin oligodendrocyte glycoprotein-induced (MOG-induced) EAE and reduced infiltration of inflammatory cells in the central nervous system. CCR6 plays a critical role in Th17 type inflammatory reactions, and CCR6 inhibition may offer an alternative approach for the treatment of these lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.